Approved indications (U.S.):

• Eylea 2 mg: wet (neovascular) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP, 0.4 mg dose in preterm infants).
• Eylea HD 8 mg: wet AMD, DME, DR, and (as of 2025) macular edema following RVO.

Common off-label uses:

• Other causes of choroidal neovascularization (for example, pathologic myopia) and some rare retinal vascular diseases, typically when similar anti-VEGF drugs are used and smaller studies or clinical experience support benefit.
• Evidence is generally moderate (clinical trials with other anti-VEGF agents plus observational data with aflibercept), but these uses are not FDA-approved.

Efficacy expectations:

• Many patients notice reduced retinal fluid and some vision improvement within the first 1–3 months; a substantial portion of patients with wet AMD or DME gain 3 or more lines (15 letters) of vision over the first year, while most others at least maintain vision.
• In RVO-related macular edema, vision and swelling often improve rapidly over the first few injections, although some patients need longer-term, regular treatment to maintain gains.
• Compared with other anti-VEGF drugs (such as ranibizumab or bevacizumab), Eylea and Eylea HD provide similar average vision outcomes when dosed equivalently, but Eylea regimens often allow longer intervals (8–16 weeks) between injections in many patients, reducing treatment burden.

General administration:

• Eylea is given only as an intravitreal injection into the eye by an ophthalmologist or trained retina specialist under sterile conditions, usually in an office or surgical setting; patients do not self-inject.
• Numbing drops and antiseptic are used before the injection; vision may be blurred for a short time afterward, so patients should arrange transportation and avoid driving until vision clears.

Typical adult dosing (Eylea 2 mg):

• Wet AMD: 2 mg (0.05 mL) every 4 weeks for the first 3 injections, then usually every 8 weeks; some patients may be extended to longer intervals or kept monthly based on response.
• Macular edema following RVO: 2 mg every 4 weeks initially; many patients need frequent injections for several months, with intervals sometimes adjusted according to swelling and vision.
• DME and DR: 2 mg every 4 weeks for the first 5 injections, then typically every 8 weeks, with some patients requiring ongoing monthly dosing or gradual extension based on disease control.

Eylea HD 8 mg dosing (adults):

• Wet AMD and DME: 8 mg (0.07 mL) every 4 weeks for the first 3 injections, then usually every 8–16 weeks, individualized to disease activity.
• DR: similar loading with three monthly 8 mg injections, then maintenance every 8–12 (up to 16) weeks as guided by retinal findings.
• Macular edema after RVO: 8 mg monthly for an initial period, with many patients able to move to every-8-week dosing thereafter; some may need continued monthly injections.

Retinopathy of prematurity (Eylea 0.4 mg):

• For eligible preterm infants with ROP, the usual dose is 0.4 mg (0.01 mL) per affected eye as a single intravitreal injection, with the option to repeat after at least 10 days if disease reactivates; this is done only by specialists experienced in ROP care.

Special instructions, missed doses, and overdose:

• Treatment schedules are individualized; some clinics use “treat-and-extend” or “as-needed” approaches to balance disease control and injection burden.
• If a scheduled injection is missed, the patient should contact the retina clinic as soon as possible to reschedule; doses should not be “doubled up” or given early without clinician guidance.
• Inadvertent overdose or too-large injected volume can sharply raise eye pressure or damage ocular structures and is managed by the ophthalmologist (for example, by removing some intraocular fluid and close monitoring).

Common side effects (usually mild to moderate):

• Eye-related effects such as conjunctival hemorrhage (small red area on the white of the eye), eye pain or irritation, temporary blurred vision, vitreous floaters, and mild increase in eye pressure occur in a noticeable minority of patients, typically within hours to days after injection and usually resolve or are manageable.
• Cataract progression and vitreous detachment can occur over time, especially in older adults, but are often difficult to separate from age-related changes.

Serious or rare adverse effects (need urgent care):

• Infection inside the eye (endophthalmitis), retinal detachment, and severe inflammation or retinal vasculitis (with or without blood vessel blockage) are rare but vision-threatening; sudden vision loss, severe eye pain, increased floaters, flashes of light, or worsening redness should prompt immediate evaluation.
• There is a small, theoretical risk of arterial thromboembolic events (such as stroke or heart attack) with intravitreal anti-VEGF drugs; overall systemic risk appears low but may be of greater concern in people with recent major cardiovascular events.

Warnings and precautions:

• Do not use in eyes with active ocular or periocular infection or active intraocular inflammation, or in patients with known severe allergy to aflibercept or formulation components.
• Use in pregnancy only if potential benefit justifies potential risk to the fetus, because VEGF is important in fetal blood-vessel development; discuss contraception and pregnancy plans with the retina specialist.
• It is not known if aflibercept passes into breast milk in meaningful amounts; clinicians often individualize decisions about breastfeeding during therapy.
• No specific dose adjustment is recommended for kidney or liver disease, but systemic exposure is low and caution is advised in patients with unstable cardiovascular disease.
• Approved for adults (for AMD, RVO, DME, DR) and for preterm infants with ROP at a special lower dose used only by specialists experienced in treating ROP.

Comparative safety vs. similar drugs:

• The overall ocular and systemic safety profile of Eylea is broadly similar to other intravitreal anti-VEGF agents; rates of serious events such as endophthalmitis and retinal detachment are low when proper sterile technique is used.
• Retinal vasculitis with vessel blockage has been reported more often with some other agents than with aflibercept, but all intravitreal injections carry small but serious risks.

Reporting side effects and safety updates:

• Patients should report any bothersome or severe side effects promptly to their eye doctor or other healthcare professional.
• In the U.S., side effects can be reported directly to the FDA through the MedWatch program (online or by phone) or to the manufacturer; up-to-date safety information is available from the FDA and from official product labeling.

Drug and product interactions:

• Because Eylea is injected into the eye with very low systemic absorption, clinically important interactions with most prescription drugs, OTC medicines, or foods are not expected.
• No specific interactions with alcohol or common dietary components are known.
• Caution is reasonable if a patient is also receiving systemic anti-VEGF therapy, as combined VEGF inhibition could theoretically increase systemic side effects.
• Use with blood thinners (such as aspirin, warfarin, or direct oral anticoagulants) is common; it may slightly increase minor bleeding on the surface of the eye (small subconjunctival hemorrhages) but has not been shown to meaningfully increase serious ocular bleeding risk.

Precautions and situations where use may be unsafe or require extra care:

• Active eye or eyelid infection, or active intraocular inflammation, is a contraindication until the problem is treated.
• Use caution in patients with a history of recent stroke, transient ischemic attack, or heart attack because of a small theoretical risk of systemic arterial thromboembolic events with anti-VEGF therapy.
• Discuss risks and benefits carefully in pregnancy and breastfeeding, given potential effects of VEGF inhibition on fetal or infant development.
• Same-day injections in both eyes are sometimes performed but require careful sterile technique and monitoring for infection in each eye.

Monitoring needs:

• Eye pressure is typically checked shortly after injection and at follow-up visits, especially in patients with glaucoma or ocular hypertension.
• Vision testing and retinal imaging (most often optical coherence tomography, OCT) are used regularly to determine whether swelling is improving and to adjust injection intervals.
• Infants treated for ROP require long-term, frequent eye examinations to monitor for disease reactivation and later visual development.

Q: How quickly will I notice improvement in my vision after an Eylea injection?
A: Some people see clearer vision or less distortion within days to weeks, but most meaningful improvements and fluid reduction are judged over the first 1–3 months of regular injections, and the goal is often to stabilize or slowly improve vision over time.

Q: How long will I need to stay on Eylea treatment?
A: Many conditions treated with Eylea, such as wet AMD and diabetic eye disease, are chronic, so injections are usually needed for years, although the interval between injections can often be lengthened once the retina is stable.

Q: Is the Eylea injection painful?
A: You may feel pressure and brief discomfort despite numbing drops, but most people tolerate the procedure well; any significant pain afterward, especially with worsening vision or redness, should be reported right away.

Q: How is Eylea different from other anti-VEGF drugs like Lucentis or Avastin?
A: All are anti-VEGF eye injections with similar average vision outcomes when dosed comparably, but Eylea and especially Eylea HD often allow longer intervals between injections in many patients, which can reduce visit and injection frequency.

Q: Can I drive or work after receiving an Eylea injection?
A: Vision is often blurred for several hours after the procedure, so it is safest to have someone drive you home and to avoid driving or operating machinery until your vision feels back to normal.

Q: What if I am pregnant or planning to become pregnant while on Eylea?
A: Because blocking VEGF could affect fetal blood-vessel development, you should discuss pregnancy plans with your eye and obstetric doctors before starting or continuing Eylea so they can weigh risks and benefits and coordinate care.

Storage (usually handled by the clinic):

• Unopened Eylea and Eylea HD vials or prefilled syringes should be kept refrigerated at 2°C–8°C (36°F–46°F), not frozen, and stored in the original carton to protect from light.
• If a patient is given the drug to bring to the eye clinic, it should be kept in the refrigerator, not used past the expiration date, and never frozen or left in a hot car.

After use and disposal:

• Injections and any remaining drug are normally prepared and disposed of by eye-care staff as medical waste; patients should not reuse vials, syringes, or needles.
• Patients who end up with unused or expired Eylea at home should return it to their clinic or pharmacy or use a local medication take-back program; they should not throw it into the household trash or sink/toilet.